DelveInsight’s Duchenne Muscular Dystrophy - Market Insights, Epidemiology and Market Forecast-2023” Reports provides an overview of the disease and global market trends of the Duchenne Muscular Dystrophy for the seven major markets i.e. United States, EU5 (France, Germany, Italy, Spain, UK) and Japan. The Report covers the therapeutics market revenue; average cost of therapy, treatment practice and Duchenne Muscular Dystrophy forecasted market share for ten years to 2023 segmented by seven major markets. In addition, the report also includes global forecast of epidemiology of Duchenne Muscular Dystrophy till 2023.
Key Coverage and Benefits
• The report will help in developing business strategies by understanding the trends shaping and driving the global Duchenne Muscular Dystrophy market.
• Identifying patient populations in the global Duchenne Muscular Dystrophy market to improve product design, pricing, and launch plans.
• Organize sales and marketing efforts by identifying the best opportunities for Duchenne Muscular Dystrophy therapeutics in each of the markets covered.
• To understand the future market competition in the global Duchenne Muscular Dystrophy therapeutics market and Insightful review of the key market drivers and barriers.
Scope
• Report covers the disease overview including etiology, path physiology, symptoms, diagnosis, disease management, and current treatment options.
• Marketed information including available prescription drugs, its patent and exclusivity details followed by drug sales till 2023.
• The Report also covers the detailed global historical and forecasted epidemiological data covering United States, EU5, Japan and rest of the word from 2013-2023.
• It also provides Duchenne Muscular Dystrophy for United States, EU5 and Japan from 2013 and forecasted Market to 2023.
Note: This report requires 7-10 business days to complete.
'
Table of Contents
• Duchenne Muscular Dystrophy overview
• Pathophysiology
• Symptoms of disease
• Etiology of disease
• Diagnosis of disease
• Treatment of disease
• Overview of Marketed drugs
• Drug Description
• Mechanism of Action
• Pharmacokinetics Properties
• Marketed Details
• Patent Information
• Patent Exclusivity Expiry Assessment United States (US)
• Patents Details
• Historical and Forecasted sales of marketed molecules in the Global Duchenne Muscular Dystrophy Market
• Global Epidemiology of Duchenne Muscular Dystrophy Forecasted to 2023
• Global Market (2013-2015)
• Global Forecasted Market (2016-2023)
• Global Market by Geography
• Market of US (2013-2015)
• Forecasted Market of US (2016-2023)
• Market of Europe
• Market of Germany (2013-2015)
• Forecasted Market of Germany (2016-2023)
• Market of United Kingdom (2013-2015)
• Forecasted Market of United Kingdom (2016-2023)
• Market of France (2013-2015)
• Forecasted Market of France (2016-2023)
• Market of Italy (2013-2015)
• Forecasted Market of Italy (2016-2023)
• Market of Spain (2013-2015)
• Forecasted Market of Spain (2016-2023)
• Market of Japan (2013-2015)
• Forecasted Market of Japan (2016-2023)
• Market of ROW (2013-2015)
• Forecasted Market of ROW (2016-2023)
• Appendix
• Report Methodology
• Consulting Services
• Disclaimer
• Report Purchase Options
• About DelveInsight
List of Tables
• Table 1: Drug Description
• Table 2: Drug, Marketed Details United States (US)
• Table 3: Drug, Patent Number Specific Patent Expiry in US (Year), 2015
• Table 4: Drug, Patent Details for US
• Table 5: Duchenne Muscular Dystrophy Drug Sales (USD Millions)
• Table 6: Global Epidemiology of Duchenne Muscular Dystrophy (2013-2023)
• Table 7: Duchenne Muscular Dystrophy Global Market (USD Millions), (2013-2015)
• Table 8: Duchenne Muscular Dystrophy Global Market (USD Millions), (2016-2023)
• Table 9: Duchenne Muscular Dystrophy US Market (USD Millions), (2013-2015)
• Table 10: Duchenne Muscular Dystrophy US Market (USD Millions), (2016-2023)
• Table 11: Duchenne Muscular Dystrophy Germany Market (USD Millions), (2013-2015)
• Table 12: Duchenne Muscular Dystrophy Germany Market (USD Millions), (2016-2023)
• Table 13: Duchenne Muscular Dystrophy United Kingdom Market (USD Millions), (2013-2015)
• Table 14: Duchenne Muscular Dystrophy United Kingdom Market (USD Millions), (2016-2023)
• Table 15: Duchenne Muscular Dystrophy France Market (USD Millions), (2013-2015)
• Table 16: Duchenne Muscular Dystrophy France Market (USD Millions), (2016-2023)
• Table 17: Duchenne Muscular Dystrophy Italy Market (USD Millions), (2013-2015)
• Table 18: Duchenne Muscular Dystrophy Italy Market (USD Millions), (2016-2023)
• Table 19: Duchenne Muscular Dystrophy Spain Market (USD Millions), (2013-2015)
• Table 20: Duchenne Muscular Dystrophy Spain Market (USD Millions), (2016-2023)
• Table 21: Duchenne Muscular Dystrophy Japan Market (USD Millions), (2013-2015)
• Table 22: Duchenne Muscular Dystrophy Japan Market (USD Millions), (2016-2023)
• Table 23: Duchenne Muscular Dystrophy ROW Market (USD Millions), (2013-2015)
• Table 24: Duchenne Muscular Dystrophy ROW Market (USD Millions), (2016-2023)
List of Figures
• Figure 1: Duchenne Muscular Dystrophy Drug Sales (USD Millions)
• Figure 2: Global Epidemiology of Duchenne Muscular Dystrophy (2013-2023)
• Figure 3: Duchenne Muscular Dystrophy Global Market (USD Millions), (2013-2015)
• Figure 4: Duchenne Muscular Dystrophy Global Market (USD Millions), (2016-2023)
• Figure 5: Duchenne Muscular Dystrophy US Market (USD Millions), (2013-2015)
• Figure 6: Duchenne Muscular Dystrophy US Market (USD Millions), (2016-2023)
• Figure 7: Duchenne Muscular Dystrophy Germany Market (USD Millions), (2013-2015)
• Figure 8: Duchenne Muscular Dystrophy Germany Market (USD Millions), (2016-2023)
• Figure 9: Duchenne Muscular Dystrophy United Kingdom Market (USD Millions), (2013-2015)
• Figure 10: Duchenne Muscular Dystrophy United Kingdom Market (USD Millions), (2016-2023)
• Figure 11: Duchenne Muscular Dystrophy France Market (USD Millions), (2013-2015)
• Figure 12: Duchenne Muscular Dystrophy France Market (USD Millions), (2016-2023)
• Figure 13: Duchenne Muscular Dystrophy Italy Market (USD Millions), (2013-2015)
• Figure 14: Duchenne Muscular Dystrophy Italy Market (USD Millions), (2016-2023)
• Figure 15: Duchenne Muscular Dystrophy Spain Market (USD Millions), (2013-2015)
• Figure 16: Duchenne Muscular Dystrophy Spain Market (USD Millions), (2016-2023)
• Figure 17: Duchenne Muscular Dystrophy Japan Market (USD Millions), (2013-2015)
• Figure 18: Duchenne Muscular Dystrophy Japan Market (USD Millions), (2015-2023)
• Figure 19: Duchenne Muscular Dystrophy ROW Market (USD Millions), (2013-2015)
• Figure 20: Duchenne Muscular Dystrophy ROW Market (USD Millions), (2016-2023)
• PTC Therapeutics Inc.
• BioMarin Pharmaceutical Inc.
• Sarepta Therapeutics Inc.
• Marathon Pharmaceuticals LLC
• Summit Therapeutics Plc
• Prosensa Holding B.V.
• GlaxoSmithKline Plc
• Celerion Inc.
• Akashi Therapeutics Inc.
• Sanofi
